JP2017502092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502092A5 JP2017502092A5 JP2016563905A JP2016563905A JP2017502092A5 JP 2017502092 A5 JP2017502092 A5 JP 2017502092A5 JP 2016563905 A JP2016563905 A JP 2016563905A JP 2016563905 A JP2016563905 A JP 2016563905A JP 2017502092 A5 JP2017502092 A5 JP 2017502092A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 69
- 239000011780 sodium chloride Substances 0.000 claims description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 41
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 239000001301 oxygen Chemical group 0.000 claims description 36
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 36
- 229910052717 sulfur Chemical group 0.000 claims description 36
- 239000011593 sulfur Chemical group 0.000 claims description 36
- 125000005842 heteroatoms Chemical group 0.000 claims description 34
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 125000001931 aliphatic group Chemical group 0.000 claims description 20
- 125000001624 naphthyl group Chemical group 0.000 claims description 18
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 101710027425 PIK3C3 Proteins 0.000 claims description 4
- 102100019473 PIK3C3 Human genes 0.000 claims description 4
- 101700014443 VPS34 Proteins 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 200000000018 inflammatory disease Diseases 0.000 claims description 4
- 230000002062 proliferating Effects 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000003455 Anaphylaxis Diseases 0.000 claims description 2
- 206010003816 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 206010007554 Cardiac failure Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 208000005017 Glioblastoma Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010019280 Heart failure Diseases 0.000 claims description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 230000001154 acute Effects 0.000 claims description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 2
- 201000005216 brain cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic Effects 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005469 ethylenyl group Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 241000162682 Heterogen Species 0.000 claims 1
- 150000002830 nitrogen compounds Chemical class 0.000 claims 1
- 230000003287 optical Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- LSBIUXKNVUBKRI-UHFFFAOYSA-N Cc1cc(C)ncn1 Chemical compound Cc1cc(C)ncn1 LSBIUXKNVUBKRI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461927064P | 2014-01-14 | 2014-01-14 | |
US61/927,064 | 2014-01-14 | ||
US201462054757P | 2014-09-24 | 2014-09-24 | |
US62/054,757 | 2014-09-24 | ||
PCT/US2015/011250 WO2015108881A1 (en) | 2014-01-14 | 2015-01-13 | Heteroaryls and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017502092A JP2017502092A (ja) | 2017-01-19 |
JP2017502092A5 true JP2017502092A5 (US07794700-20100914-C00152.png) | 2018-02-08 |
Family
ID=53543368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016563905A Pending JP2017502092A (ja) | 2014-01-14 | 2015-01-13 | ヘテロアリール及びその使用 |
Country Status (4)
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA032458B1 (ru) | 2014-01-14 | 2019-05-31 | Милленниум Фармасьютикалз, Инк. | Гетероарилы и их применение |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP6997462B2 (ja) | 2016-02-19 | 2022-01-17 | スプリント バイオサイエンス アクティエボラーグ | がんおよび糖尿病の治療に有用な6-アリール-4-モルホリン-1-イルピリドン化合物 |
JP6858984B2 (ja) | 2016-02-19 | 2021-04-14 | スプリント バイオサイエンス アクティエボラーグ | がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物 |
US11208423B2 (en) | 2017-08-23 | 2021-12-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds |
ES2902346T3 (es) * | 2017-08-23 | 2022-03-28 | Sprint Bioscience Ab | Compuestos de azaindolilpiridona y diazaindolilpiridona |
ES2910157T3 (es) | 2017-08-23 | 2022-05-11 | Sprint Bioscience Ab | Compuestos de morfolinilpiridona |
IL302356A (en) | 2017-08-23 | 2023-06-01 | Sprint Bioscience Ab | Pyridylpyridone compounds |
KR20220079851A (ko) * | 2019-09-11 | 2022-06-14 | 프렐루드 테라퓨틱스, 인코포레이티드 | Cdk 억제제 및 약제로서의 이의 용도 |
TW202320797A (zh) * | 2021-08-13 | 2023-06-01 | 美商迪賽孚爾製藥有限公司 | 使用vps34抑制劑之組合療法 |
WO2024061371A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州威诺森医药科技有限公司 | 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用 |
WO2024102026A1 (en) * | 2022-11-10 | 2024-05-16 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1562911B1 (en) | 2002-11-01 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
CA2545384A1 (en) | 2003-11-10 | 2005-05-26 | Merck Sharp & Dohme Limited | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
EP1814856A1 (en) | 2004-11-12 | 2007-08-08 | Galapagos N.V. | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
WO2007135398A1 (en) | 2006-05-22 | 2007-11-29 | Astrazeneca Ab | Indole derivatives |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
WO2008025821A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
NZ578159A (en) | 2006-12-04 | 2012-01-12 | Astrazeneca Ab | Antibacterial polycyclic urea compounds |
EA200900799A1 (ru) | 2006-12-22 | 2009-12-30 | Новартис Аг | Гетероарилгетероарильные соединения как ингибиторы cdk, предназначенные для лечения рака, воспаления и борьбы с вирусными инфекциями |
UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
CA2694275A1 (en) | 2007-07-26 | 2009-01-29 | Novartis Ag | Organic compounds |
US7928140B2 (en) | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
WO2009039140A1 (en) | 2007-09-17 | 2009-03-26 | Smithkline Beecham Corporation | Pyridopyrimidine derivatives as pi3 kinase inhibitors |
JP2011500823A (ja) | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
CA2725014C (en) | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
WO2009147187A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
EP2303886A2 (en) | 2008-06-24 | 2011-04-06 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
WO2010007100A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
CN102238950B (zh) | 2008-08-04 | 2014-05-07 | Chdi基金会股份有限公司 | 某些犬尿氨酸-3-单加氧酶抑制剂、药物组合物以及使用方法 |
JP2012508239A (ja) | 2008-11-11 | 2012-04-05 | イーライ リリー アンド カンパニー | P70s6キナーゼ阻害剤およびmtor阻害剤の併用療法 |
WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
TW201026695A (en) | 2008-12-12 | 2010-07-16 | Astrazeneca Ab | Piperidine compounds and uses thereof-596 |
CA2763099A1 (en) | 2009-05-22 | 2010-11-25 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
US8435980B2 (en) * | 2009-07-15 | 2013-05-07 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
MX2012002761A (es) | 2009-09-04 | 2012-04-19 | Novartis Ag | Bipiridinas utiles para el tratamiento de enfermedades proliferativas. |
US8614226B2 (en) | 2010-02-05 | 2013-12-24 | Merck Patent Gmbh | Hetaryl-[1,8]naphthyridine derivatives |
SG186871A1 (en) | 2010-07-05 | 2013-02-28 | Merck Patent Gmbh | Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
ES2550939T3 (es) | 2010-07-16 | 2015-11-13 | Nivalis Therapeutics, Inc. | Nuevos compuestos de dihidropiridin-2-(1H)-ona como inhibidores de la S-nitrosoglutatión reductasa y antagonistas del receptor de la neurocinina-3 |
JP2013532688A (ja) * | 2010-07-26 | 2013-08-19 | ブリストル−マイヤーズ スクイブ カンパニー | Cyp17阻害剤として有用なスルホンアミド化合物 |
WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US8478700B2 (en) | 2010-08-11 | 2013-07-02 | Brightedge Technologies, Inc. | Opportunity identification and forecasting for search engine optimization |
NZ607087A (en) | 2010-08-11 | 2015-05-29 | Millennium Pharm Inc | Heteroaryls as inhibitors of pi3k and for the treatment of proliferative, inflammatory, or cardiovascular disorders |
WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
JP2013542967A (ja) | 2010-11-17 | 2013-11-28 | ノバルティス アーゲー | 3−(アミノアリール)−ピリジン化合物 |
BR112013015449A2 (pt) | 2010-12-21 | 2016-09-20 | Novartis Ag | compostos de bi-heteroarila como inibidores de vps23 |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
WO2012101062A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses |
WO2012101064A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | N-acyl pyrimidine biaryl compounds as protein kinase inhibitors |
WO2012101066A1 (en) | 2011-01-28 | 2012-08-02 | Novartis Ag | Pyridine biaryl amine compounds and their uses |
DE102011077104A1 (de) | 2011-06-07 | 2012-12-13 | Siemens Aktiengesellschaft | Verfahren zur Gewinnung von metallhaltigen Wertstoffen aus einem metallhaltige Wertstoffe enthaltenden suspensionsartigen Massestrom |
KR101502500B1 (ko) | 2011-07-01 | 2015-03-16 | 주식회사 엘지화학 | 비수 전해액 및 이를 이용한 리튬 이차전지 |
UA111382C2 (uk) | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
UY34538A (es) | 2011-12-23 | 2013-06-28 | Millennium Pharm Inc | Heteroarilos y usos de los mismos |
AU2013222345B2 (en) | 2012-02-22 | 2017-09-07 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
US9315499B2 (en) | 2012-04-05 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Cytomegalovirus inhibitor compounds |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
EP2903613B1 (en) | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
WO2014083327A1 (en) | 2012-11-27 | 2014-06-05 | Md Pharma Ab | Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy |
GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
BR112015016580A2 (pt) | 2013-01-11 | 2017-07-11 | Fujifilm Corp | composto heterocíclico contendo nitrogênio ou sal deste |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
EA032458B1 (ru) | 2014-01-14 | 2019-05-31 | Милленниум Фармасьютикалз, Инк. | Гетероарилы и их применение |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
-
2015
- 2015-01-13 WO PCT/US2015/011250 patent/WO2015108881A1/en active Application Filing
- 2015-01-13 US US15/111,429 patent/US10202373B2/en active Active
- 2015-01-13 EP EP15737300.2A patent/EP3094326A4/en not_active Withdrawn
- 2015-01-13 JP JP2016563905A patent/JP2017502092A/ja active Pending